FundedIQ
Health Care

Ratio Therapeutics: Funding, Investors & Team (Aug 2026)

Ratio Therapeutics, a pharmaceutical firm in the discovery to early clinical phase, uses a variety of cutting-edge technologies to provide the best-in-class tailored radiotherapeutics for the treatment of cancer. The TrilliumTM targeting scaffold from Ratio Therapeutics combines best-in-class chelation technology with pharmacokinetic modification to produce unique small molecules that can target a variety of cancer targets. Our chemicals allow for therapeutic and imaging radioisotopes, or "theranostics." Compound selection is faster and reduced in risk because to our platform's adaptability and small-scale imaging patient studies.

ratiotx.com LinkedIn Boston, United States 1-10 employees
Pharmaceutical
Total raised
$20.0M
Rounds
1
Latest
Series A
Feb 2023

Ratio Therapeutics has raised $20.0M across 1 funding round on record, the most recent a Series A of $20.0M announced in Feb 2023.

That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.

Ratio Therapeutics Company Profile and Key Stats

Total funding raised
$20.0M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series A
$20.0M in Feb 2023
Employees
1-10
reported band
Headquarters
Boston, United States

Latest funding round on record: Feb 2023.

Ratio Therapeutics Funding Rounds

Date
Round
Amount
Series A
$20.0M

Ratio Therapeutics Founders and Leadership Team

Name
Role
Contact
Jack Hoppin
CEO
Locked

Contact details for the Ratio Therapeutics team: 1 of 1 has an email address on file.

Start 14-day free trial →

Ratio Therapeutics Funding Compared to Other Health Care Startups

Segment
Companies
Median round
3,653
$4.7M
29,722
$7.5M
8,352
$15M

Ratio Therapeutics' latest round of $20.0M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Ratio Therapeutics in Health Care and Boston

Companies Similar to Ratio Therapeutics

https://metriport.com

Series A $26.0M

There are too many reasons why Healthcare is unaffordable in the U.S, but one of the largest is waste. Up to…

Series A $17.0M

Serif Health provides healthcare price intelligence and contract management solution.

Private Equity $5.7M

Switchboard Health provides virtual care solutions to payers, health systems, employers, and at-risk…

Undisclosed round $5.0M

Astek Diagnostics has designed a system that helps doctors choose the right antibiotics for patients…

Seed $750k

TECLens is developing a crosslinking technology that can effectively address vision problems in both healthy…

Series A $10.0M

Healthcare Shares operates as a crowdfunding portal for the transformative medical innovations of the future.

Undisclosed round $1.5M

Gradient Health collaborates with medical data providers worldwide to assemble diseases and conditions for AI…

Undisclosed round $3.0M

Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s…

Series A $14.0M

Happy Health is a mission-driven technology company committed to transforming mental health awareness through…

Undisclosed round $75.0M

Leal Therapeutics creates new treatments for patients.

Series A $30.0M

Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical…

Series A $18.3M

Ratio Therapeutics Funding FAQs

What does Ratio Therapeutics do?

Ratio Therapeutics, a pharmaceutical firm in the discovery to early clinical phase, uses a variety of cutting-edge technologies to provide the best-in-class tailored radiotherapeutics for the treatment of cancer. The TrilliumTM targeting scaffold from Ratio Therapeutics combines best-in-class chelation technology with pharmacokinetic modification to produce unique small molecules that can target a variety of cancer targets. Our chemicals allow for therapeutic and imaging radioisotopes, or "theranostics." Compound selection is faster and reduced in risk because to our platform's adaptability and small-scale imaging patient studies.

How much funding has Ratio Therapeutics raised?

Ratio Therapeutics has raised $20.0M across 1 round on record. The most recent is a Series A of $20.0M announced in Feb 2023.

When did Ratio Therapeutics last raise funding?

Ratio Therapeutics' most recent funding round on record is a Series A of $20.0M, announced in Feb 2023.

Who is the CEO of Ratio Therapeutics?

Jack Hoppin is listed as CEO at Ratio Therapeutics.

Where is Ratio Therapeutics headquartered?

Ratio Therapeutics is based in Boston, Massachusetts, United States.

How many employees does Ratio Therapeutics have?

Ratio Therapeutics is in the 1-10 employee band.

How does Ratio Therapeutics' funding compare to other Health Care startups?

Ratio Therapeutics' latest round of $20.0M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.

About FundedIQ's Ratio Therapeutics Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ratio Therapeutics is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.